Entering text into the input field will update the search result below

Expanded label for Edwards' SAPIEN 3 valve OK'd in Europe

Sep. 19, 2016 9:30 AM ETEdwards Lifesciences Corporation (EW) StockEWBy: Douglas W. House, SA News Editor
  • Edwards Lifesciences (NYSE:EW) receives CE Mark clearance for the uses of its SAPIEN 3 transcatheter heart valve in patients with severe aortic stenosis who are at intermediate risk for an open-heart surgical procedure. The valve was originally approved in Europe in January 2014 for the same patients are at high risk for open heart surgery.
  • The FDA approved the new indication last month. It was originally approved in the U.S. for high risk patients in June 2015.
  • Previously: FDA OKs expanded use of Edwards' SAPIEN 3 heart valve (Aug. 18)

Recommended For You

More Trending News

About EW Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
EW--
Edwards Lifesciences Corporation